We have previously shown that effective ISV can be achieved using Flt3-ligand (Flt3L) to mobilize DCs, radiotherapy to release tumor Ag and load DCs, and TLR agonists (TLRa) to activate Ag-loaded DCs7. Here, FLT3LG is linked to neoplasm.